CGS-21680

CGS-21680 is a pivotal molecule within neuropharmacology, specifically as an agonist for the adenosine A2A subtype receptor. While its current application remains predominantly in research, it offers potential insights into the deeper mechanisms of neuronal transmission.

Chemical Characteristics[edit | edit source]

Molecular Form: CGS-21680 is typically encountered as an organic hydrochloride salt.
Molecular Weight: It has a molecular weight of 536.0 g/M.

Solubility: Up to 3.4 mg/mL in DMSO (Dimethyl sulfoxide). Up to 20 mg/mL in 45% (w/v) aqueous 2-hydroxypropyl-β-cyclodextrin.

Research Implications[edit | edit source]

The prime interest in CGS-21680 emanates from its role as a high-affinity, subtype-specific analogue for adenosine, a naturally occurring neurotransmitter. Such analogues help researchers to elucidate the role of adenosine in various physiological and neurological processes.

Neuronal Transmission: By mimicking the effects of adenosine in a targeted manner, CGS-21680 provides insights into how adenosine receptors influence neuronal transmission^[1].
Respiratory Rhythmicity: The drug has been instrumental in respiratory studies, especially regarding the pre-Bötzinger complex, a neural structure believed to play a role in rhythm generation. Specifically, A2A receptors are postulated to influence this rhythm generation^[2].

Therapeutic Potential[edit | edit source]

While CGS-21680 serves as a valuable research tool, it has not yet garnered approval for therapeutic use. However, given its role in elucidating the functions of adenosine receptors, there's potential for its analogues or derivatives to contribute to therapeutic strategies in the future.

Limitations and Considerations[edit | edit source]

As with all research compounds, users of CGS-21680 must be aware of its specificities, including its solubility parameters, and should use it judiciously, understanding that its primary role is in experimental applications and not therapeutic interventions.

References[edit | edit source]

Stone, T. W., & Ceruti, S. (2007). Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology, (193), 535-587. Herlenius, E., & Lagercrantz, H. (2004). Neurotransmitters and neuromodulators during early human development. Early human development, 79(1), 21-37.

↑ Stone, T. W., & Ceruti, S. (2007). Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology, (193), 535-587.
↑ Herlenius, E., & Lagercrantz, H. (2004). Neurotransmitters and neuromodulators during early human development. Early human development, 79(1), 21-37.

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD

Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

[1] Stone, T. W., & Ceruti, S. (2007). Adenosine receptors and neurological disease: Neuroprotection and neurodegeneration. Handbook of Experimental Pharmacology, (193), 535-587.

[2] Herlenius, E., & Lagercrantz, H. (2004). Neurotransmitters and neuromodulators during early human development. Early human development, 79(1), 21-37.

[1]

[2]